research discussion
DESCRIPTION
Moderated by : Professor Jinsil SeongTRANSCRIPT
1
Research Discussion Moderated by : Professor Jinsil Seong
22
What has been published?
3#XXXXXXX — Company Confidential
CyberKnife for Liver Cancer Inoperable primary hepatocellular carcinoma
Combined with transarterial chemoembolization (TACE)1
As sole treatment when other local therapies not indicated2
For recurrences3
Cholangiocarcinoma in combination with chemotherapy4
As a bridge to transplant7
Liver metastasesFrom various primary tumors5
In patients treated multiple times61Choi et al. BMC Cancer 2008;8:351.
2Louis et al. Technol Cancer Res Treat 2010;9:479-487.3Huang et al. International journal of radiation oncology, biology, physics 2012;84:355-361.
4Park et al. Gut Liver 2010;4:103-105.5Ambrosino et al. Anticancer Res 2009;29:3381-3384.
6Lanciano et al. Front Oncol 2012;2:23.7O’Connor et al. Liver Transplant, 2012 Aug;18(8):949-54.
4
CyberKnife for Liver Cancer
Korea institute of Radiological and Medical Science
SBRT for inoperable HCC as a salvage after incomplete TACE Retrospective 2008-2011, 50 patients (C-P A/B, tumor <10cm, 1-5 TACE before RT) Median prescribed dose: 57 Gy in 3 fractions (range, 42-60 Gy) Response rate at 6 mo: 76.6% (CR in 38.3%, PR in 38.3%) 2 Y LC: 94.6%, 2 Y OS: 68.7%
Korea
Kang et al. Cancer. 2012;118:5424-31.
Kwon et al. BMC Cancer. 2010 Sep 3;10:475
The Catholic Univ. of Korea
Long term effect of SBRT for HCC ineligible for local treatment Retrospective 2004-2007, 42 patients (C-P A/B, tumor <100 cc, without PVTT) Median prescribed dose: 33 Gy in 3 fractions (range, 30-39 Gy) In-field response rate at 1 mo: 85.8% (CR in 59.6%, PR in 26.2%) 1Y OS: 92.9%, 3Y OS: 58.6%
5
CyberKnife for Liver Cancer
National Defense Medical Center
SBRT for inoperable recurrent HCC Retrospective 2008-2009, 36 patients (recurrent tumor after curative treatment) Median prescribed dose: 37 Gy in 4-5 fractions (range, 25-48 Gy) Response rate: 58.6% (CR in 22%, PR in 36.6%) 2Y OS: 64% Matched-pair analysis with 138 patients given other or no treatment
- 2Y OS: 72.6% in SBRT group, 42.1% in control group (p=0.013)
National Defense Medical Center
SBRT or 3DRT for PVTT in HCC patients Prospective 2002-2004, 43 patients (22 in SBRT group, 21 in 3DRT group) Median prescribed dose- SBRT: 45 Gy in 15 fractions/ 3DRT: 45 Gy in 25 fractions Response rate: 79% (CR in 7%, PR in 71%) 1Y OS: 100% in CR, 56% in PR
Taiwan
Huang et al. IJROBP 2012 Oct 1;84(2):355-61
Lin CS et al. JJCO 2006 Apr;36(4):212-7
6
CyberKnife for Liver Cancer
Tianjin Cancer Hospital
Radiosurgery for primary HCC Retrospective 2006-2008, 17 patients (stage I-III, 12 patients received local treatment) Median prescribed dose: 45 Gy in 3-8 fractions (range, 39-52 Gy) Response rate: 100%
China
Liu et al. Zhonghua Zhong Liu Za Zhi. 2010 Mar;32(3):229-33.
7
CyberKnife for Liver Cancer
University Hospital Domaine Universitaire Sart Tilman, Belgium
SBRT for inoperable HCC Retrospective 25 patients (CP-A/B, single tumor) Median prescribed dose: 45 Gy in 3 fractions 2Y local control: 95% 1Y OS: 79%, 2Y OS: 52%
Baylor Univ. Medical center Dallas, USA
Long-Term Outcomes of SBRT in HCC as a Bridge to Transplantation Retrospective 2005-2010, 10 patients Median prescribed dose: 51 Gy in 3 fractions (range, 33-54 Gy) CR in 27%, 5Y OS & DFS: 100%
Europe / US
Louis et al. TCRT.Volume 9, Number 5, October 2010
Oconnor et al. Liver Transl 2012 Aug;18:949-954
8
CyberKnife for Liver Cancer
Indiana Univ. School of Medicine, USA
Phase I feasibility trial of SBRT for HCC Prospective, Dose escalation 21 patients (CP-A/B, tumor ≤ 6 cm) Protocol scheme:
36 Gy in 3 fractions > planned escalation until reaching MTD 2Y local control: 100%, 1Y OS: 75%, 2Y OS: 60%
Europe / US
Price et al. Cancer. 2012 Jun 15;118(12):3191-8
Cardenes et al. Clin Transl Oncol. 2010 Mar;12(3):218-25
Indiana Univ. School of Medicine, USA
Radiosurgery for primary HCC Retrospective 2006-2008, 17 patients (stage I-III, 12 patients received local treatment) Median prescribed dose: 45 Gy in 3-8 fractions (range, 39-52 Gy) Response rate: 100%
9
CyberKnife for Liver Cancer
Centre Oscar Lambret, Lille, France
IG-IMRT for unresectable liver metastasis Retrospective 2007-2009, 42 patients Median prescribed dose: 40 Gy in 4 fractions/45 Gy in 3 fractions 1Y LC: 90%, 2Y LC: 86% 1Y OS: 94%, 2Y OS: 48%
Europe / US
Vautraver et al. IJROBP 2011 Nov 1;81:39-47
10#XXXXXXX — Company Confidential
TomoTherapy for Liver Cancer
• Locally advanced• Large lesions• Multiple lesions • Liver metastases
11#XXXXXXX — Company Confidential
TomoTherapy for Liver Cancer
The Catholic Univ. of Korea
Simultaneous multi-target RT for HCC with multiple extrahepatic mets Retrospective 42 patients (152 intra and extrahepatic metastases) Median prescribed dose: 33 Gy in 3 fractions (range, 30-39 Gy) In-field response rate at 1 mo: 85.8% (CR in 59.6%, PR in 26.2%) 1Y OS: 92.9%, 3Y OS: 58.6%
Yonsei Univ. of Korea
Optimal RT technique for locally advanced HCC 2006-2007, 12 patients, 60 Gy in 30 fractions Comparison of plans(3D-CRT, linac-based IMRT and helical tomotherapy) Lower irradiated liver volume at 40, 50 and 60 Gy Superior tumor coverage
Korea
Jang et al. IJROBP 2009 Nov 1;81:39-47
Lee et al. JJCO. 2011 Jul;41(7):882-9
12#XXXXXXX — Company Confidential
TomoTherapy for Liver Cancer
Shin-Kong Memorial Hospital, National Yang-Ming University
Angiogenic blockade and RT in HCC Retrospective 2007-2008, 23 patients, RT + sunitinib Median prescribed dose: 52.5 Gy in 15 fractions Response rate: 74% 1Y OS: 70%
Vrije Univ. Brussel, Belgium
Phase II study in the multidisciplinary Tx of oligometastatic CRC 24 patients(≤ 5 metastases, in lung, liver, LN) Median prescribed dose: 50 Gy in 5 fractions Response rate in metastatic lesion: 55% 1Y LC: 54%, 1Y PFS: 14%, 1Y OS: 78%
Chi et al. IJROBP. 2010 Sep 1;78(1):188-93
Engels B et al. Radiation Oncology. 2012 Mar 16;7:34
1313
Current Research Interests?
14
HCC studies and protocols
Korea CK led by Kim of Korea Cancer Center Hospital, multi-institution studies
Incomplete response after TACE? Sample size? 60Gy in 3? 2-year local control, OS?
Taiwan CK led by Ren of Tri-Service General Hospital, Taiwan, multi-institution studies
TACE ineffective or unsuitable, sample size 150 Randomized, arm A – SABR and/or Thalidomide/Sorafenib, 4.5-6.5 per faction, 1F per day,
10 fractions, total 45-60Gy; arm B – TACE and/or Thalidomide/Sorafenib or observation Safety profile, local control and PFS, OS in two years
China CK led by Song of Tianjin Cancer Hospital, multi-institution studies
Naïve patients, sample size 100 45Gy in 3 OS at 1 and 2-year; local control, PFS and acute and late toxicities
Korea TT led by Seong of Yonsei University Medical College
9-13Gy x 4f
1515
Future Research Direction?
16#XXXXXXX — Company Confidential
Standardizing protocol?
Criteria in selecting the patients? Impact of target delineation strategies?Dose and fractionation scheme?The treatment margins for CK or TT?Ways of image guidance and motion management?
How can we connect the guidelines to medical associations in different countries?
SBRT (CyberKnife) and IG-IMRT (TomoTherapy)
17#XXXXXXX — Company Confidential
Future Research and Regional Synergy
Future research areas/direction? Possible regional collaboration ?